Smart Drug Delivery Systems Market Report 2026

The smart drug delivery systems market size has grown rapidly in recent years. It will grow from $15.06 billion in 2025 to $18 billion in 2026 at a compound annual growth rate (CAGR) of 19.5%. The growth in the historic period can be attributed to limitations of conventional drug delivery, growth in chronic diseases, advances in biomaterials, improved patient adherence focus, pharmaceutical innovation.

The smart drug delivery systems market size is expected to see rapid growth in the next few years. It will grow to $33.15 billion in 2030 at a compound annual growth rate (CAGR) of 16.5%. The growth in the forecast period can be attributed to personalized therapy demand, expansion of biologics usage, digital health integration, regulatory support for combination devices, innovation in nanotechnology. Major trends in the forecast period include integration of AI-controlled dosing, growth of implantable delivery systems, rising demand for targeted drug delivery, adoption of wireless connectivity, expansion of combination drug-device products.

The rising prevalence of chronic diseases is expected to drive the growth of the smart drug delivery systems market in the coming years. Chronic diseases are long-term health conditions that develop gradually and often have complex causes. Their increasing prevalence is linked to aging populations, environmental factors, and disparities in healthcare access. Smart drug delivery systems offer a promising solution for managing chronic diseases by improving medication effectiveness and enhancing patient adherence. For example, in April 2025, the Centers for Disease Control and Prevention (CDC), a US-based federal agency, reported that in 2023, approximately 194 million U.S. adults, or 76.4%, had at least one chronic condition. Prevalence rates were 59.5% among young adults, 78.4% among midlife adults, and 93% among older adults. Therefore, the growing prevalence of chronic diseases is fueling the smart drug delivery systems market.

Key companies in the smart drug delivery systems market are focusing on innovative solutions, such as advanced on-body delivery platforms, to improve injectable therapy administration, enhance patient convenience, and ensure accurate dosing. Advanced on-body delivery platforms are wearable systems that automatically and precisely deliver medication over time, improving safety, adherence, and convenience. For instance, in October 2024, Stevanato Group, an Italy-based pharmaceutical solutions provider, launched its large-volume Vertiva 10 mL on-body delivery system platform at CPHI Milan. The platform is designed to support high-volume injectable therapies with improved usability, safety, and patient adherence, meeting the growing demand for patient-centric drug delivery solutions.

In October 2023, Novo Nordisk A/S, a Denmark-based pharmaceutical company, acquired Biocorp Production SA for $164.5 million. This acquisition strengthens Novo Nordisk’s capabilities in developing innovative connected devices and drug delivery solutions, such as Mallya, a smart add-on device for pen injectors. Biocorp is a France-based designer and manufacturer of medical devices and drug delivery systems for pharmaceutical companies.

Major companies operating in the smart drug delivery systems market are Johnson & Johnson, Abbott Laboratories, Novartis International AG, Medtronic plc, Eli Lilly and Company, Novo Nordisk, Becton Dickinson and Company, Baxter International Inc, Phillips-Medisize Corporation, ResMed Inc, West Pharmaceutical Services Inc, Insulet Corporation, Owen Mumford Ltd, Sonceboz, H&T Presspart Manufacturing Ltd, E3D Elcam Drug Delivery Devices, CeQur Corporation, Ypsomed Holding AG, Nemera, Gerresheimer AG, Haselmeier AG, SHL Medical, Aptar Pharma.

North America was the largest region in the smart drug delivery systems market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the smart drug delivery systems market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the smart drug delivery systems market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have affected the smart drug delivery systems market by increasing costs for imported sensors, connectivity modules, microelectronics, and precision injection components. Hospitals, clinics, and home care providers in Asia-Pacific and Europe are facing higher procurement costs for connected inhalers, wearable injectors, and smart pens. These increases can slow adoption in chronic disease management. However, tariffs are driving local manufacturing of smart delivery devices and electronics, strengthening supply resilience in the smart drug delivery systems market.

The smart drug delivery systems market research report is one of a series of new reports that provides smart drug delivery systems market statistics, including smart drug delivery systems industry global market size, regional shares, competitors with a smart drug delivery systems market share, detailed smart drug delivery systems market segments, market trends and opportunities, and any further data you may need to thrive in the smart drug delivery systems industry. This smart drug delivery systems market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Smart drug delivery systems are advanced technologies designed to enhance the efficacy, safety, and targeted delivery of pharmaceutical compounds to specific sites in the body. These systems use various approaches to control drug release, improve bioavailability, and reduce side effects.

The main product types in smart drug delivery systems include connected inhalers, connected autoinjectors, connected pen injectors, connected wearable injectors, add-on sensors, and others. Connected inhalers are electronic monitoring systems integrated with inhalers that track drug usage and may assess the technique of device use. They are applied across therapeutic areas such as metabolic disorders, neurological disorders, respiratory disorders, hormonal disorders, and others, using drug delivery modes including injectable, inhalation, and oral. The end users include hospitals, clinics, home care, ambulatory care settings, and other healthcare facilities.

The smart drug delivery systems market consists of revenues earned by entities by providing services such as personalized drug delivery, targeted treatment, diagnostic integration, remote monitoring, and feedback mechanisms. The market value includes the value of related goods sold by the service provider or included within the service offering. The smart drug delivery systems market also includes sales of products including microfluidic devices, transdermal drug delivery patches, electroceutical devices, and remote-controlled drug delivery devices. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.